{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:21Z","timestamp":1790665641429,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":788,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1093\/annonc\/mdx274","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T03:05:57Z","timestamp":1496027157000},"page":"2191-2198","source":"Crossref","is-referenced-by-count":18,"title":["Reduced-intensity versus reduced-toxicity myeloablative fludarabine\/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Le Bourgeois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mar\u00e7ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.O.","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Contentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Rorhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"N\u2019Guyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1093\/annonc\/mdx274_bb0010","first-page":"1039","article-title":"Advancement in high dose therapy and autologous stem cell rescue in lymphoma","volume":"7","author":"Isidori","year":"2015","journal-title":"World J Stem Cells"},{"issue":"2","key":"10.1093\/annonc\/mdx274_bb0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2013.08.016","article-title":"Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation","volume":"89","author":"Gkotzamanidou","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdx274_bb0020","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3109\/10428194.2014.975803","article-title":"Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma","volume":"56","author":"Faroog","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1093\/annonc\/mdx274_bb0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"10.1093\/annonc\/mdx274_bb0030","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdx274_bb0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11899-016-0319-0","article-title":"Allogeneic stem cell transplantation for non-Hodgkin lymphoma","volume":"11","author":"Bhatt","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1093\/annonc\/mdx274_bb0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bmt.1704233","article-title":"Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin\u2019s lymphoma","volume":"32","author":"Seropian","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1093\/annonc\/mdx274_bb0045","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indication for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx274_bb0050","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1093\/annonc\/mdx274_bb0055","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/annonc\/mdw124","article-title":"Reduced intensity allogeneic stem cell transplantation for follicular relapsing after an autologous transplant achieves durable long term disease control. An analysis from the lymphoma working party of the EMBT","volume":"28","author":"Robinson","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx274_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: current practice in Europe 2009","volume":"45","author":"Ljungman","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdx274_bb0065","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2012.66","article-title":"The EBMT activity survey: 1990-2010","volume":"47","author":"Passweg","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1093\/annonc\/mdx274_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx274_bb0075","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx274_bb0080","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regiments: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1093\/annonc\/mdx274_bb0085","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bmt.2014.133","article-title":"Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT","volume":"49","author":"Kharfan-Dabaja","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1093\/annonc\/mdx274_bb0090","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.leukres.2015.04.009","article-title":"Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"39","author":"Kharfan-Dabaja","year":"2015","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdx274_bb0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Statist Med"},{"key":"10.1093\/annonc\/mdx274_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mdx274_bb0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"4","key":"10.1093\/annonc\/mdx274_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdx274_bb0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx274_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as non-parametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"key":"10.1093\/annonc\/mdx274_bb0125","unstructured":"Package \u2018MatchIt\u2019 2015. http:\/\/cran.project.org\/web\/packages\/MatchIt\/MatchIt.pdf (18 May 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdx274_bb0130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cncr.29087","article-title":"Reduced-toxicity conditioning with fludarabine, once-daily busulfan, and antithymocyte globulins prios to allogeneic stem cell transplantation: results of multicenter prospective phase 2 trial","volume":"15","author":"Mohty","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdx274_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/157488608783333899","article-title":"Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children","volume":"3","author":"Krivoy","year":"2008","journal-title":"Curr Drug Saf"},{"key":"10.1093\/annonc\/mdx274_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3324\/haematol.2013.089888","article-title":"Glutatione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation","volume":"99","author":"Bonifazi","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1093\/annonc\/mdx274_bb0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1093\/annonc\/mdx274_bb0150","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"32","author":"Valdez","year":"2008","journal-title":"Leuk Res"},{"issue":"1","key":"10.1093\/annonc\/mdx274_bb0155","first-page":"1","article-title":"The role of DNA mismatch repair in drug resistance","volume":"4","author":"Flink","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdx274_bb0160","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2014.105981","article-title":"Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies","volume":"99","author":"Oudin","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1093\/annonc\/mdx274_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hon.985","article-title":"Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning","volume":"29","author":"Hamadani","year":"2011","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx274_bb0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bbmt.2013.03.016","article-title":"Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia","volume":"19","author":"Chen","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1093\/annonc\/mdx274_bb0175","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1093\/annonc\/mdx274_bb0180","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfont allogeneic stem-cell transplantation for patients with nonlocalized untraeted peripheral T-cell lymhoma: an intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx274_bb0185","doi-asserted-by":"crossref","first-page":"1484.","DOI":"10.1038\/bmt.2013.86","article-title":"Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response","volume":"48","author":"Robles","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdx274_bb0190","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx274_bb0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1093\/annonc\/mdx274_bb0200","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2015.174","article-title":"Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies","volume":"50","author":"Yerushalmi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1093\/annonc\/mdx274_bb0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdu503","article-title":"90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas","volume":"26","author":"Bouabdallah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx274_bb0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: update safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1093\/annonc\/mdx274_bb0215","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/9\/2191\/19709815\/mdx274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:27:02Z","timestamp":1624696022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341935238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S092375341935238X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx274","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}